Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
TV

NASDAQ · TVGN

Tevogen Bio Holdings Inc.

Healthcare · Biotechnology

$5.90

Down-$0.15 (-2.48%)

Updated Nov 2, 2026, 6:42 AM

SID Score

2.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
85.1M
P/E ratio
-2.7
Dividend yield
0.00%
52-week range
$3.64 – $32.50
Volume
2.99K
Avg. volume
795.94K

Price performance · TVGN

TVGN price history

1M range · 0 trading sessions · Daily adjusted prices

TVGN does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest TVGN news

The latest Smart Investors Daily articles mentioning TVGN.

Stock researchCompany · Overview

TVGN research

Overview

Company profile and research snapshot.

Company profile

Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
TVGN recent ratings
DateFirmRatingTarget
Mar 4, 2026D. Boral CapitalHold—
Mar 3, 2026D. Boral CapitalBuy—
Nov 20, 2025D. Boral CapitalBuy—
Sep 4, 2025D. Boral CapitalBuy—
Aug 18, 2025D. Boral CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 8, 2026

UPDATE – Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of HRK Healthcare LLC

WARREN, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Tevogen Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN), an integrated healthcare enterprise combining biopharma, artificial intelligence, and healthcare services to improve the affordability and accessibility of life-saving medicines, today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to evaluate a potential transaction with HRK Healthcare LLC (“HRK”). If consummated, the proposed transaction co

Yahoo · Oct 8, 2026

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of HRK Healthcare LLC

WARREN, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Tevogen Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN), an integrated healthcare enterprise combining biopharma, artificial intelligence, and healthcare services to improve the affordability and accessibility of life-saving medicines, today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to evaluate a potential transaction with HRK Healthcare LLC (“HRK”). If consummated, the proposed transaction co

Yahoo · Sep 30, 2026

Tevogen Regains Compliance with Nasdaq Global Market Continued Listing Requirements

Both previously disclosed Nasdaq compliance matters are now closedWARREN, N.J., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Tevogen Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN), an integrated healthcare enterprise combining biotechnology, artificial intelligence, and healthcare services to improve the affordability and accessibility of life-saving medicines, today announced that it received written notice from The Nasdaq Stock Market LLC (“Nasdaq”)on September 29, 2026, confirming that the Company ha

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By